Key Events This Week
18 May: Valuation shifts signal renewed price attractiveness
19 May: Upgraded to Strong Buy on robust financials
21 May: Sharp open interest surge signals bullish positioning
22 May: Intraday low amid price pressure and volatile trading
22 May: Open interest spikes 27.6% despite price weakness
22 May: Week closes at ₹2,259.20 (-2.83%) vs Sensex +0.50%
18 May: Valuation Shifts Signal Renewed Price Attractiveness
Glenmark Pharmaceuticals began the week with a positive valuation reassessment. The company’s price-to-earnings (P/E) ratio stood at 26.82, marking a shift to very attractive valuation territory relative to its historical averages and sector peers. The price-to-book value ratio was 6.83, and the PEG ratio was exceptionally low at 0.03, indicating that earnings growth was not fully priced in. These metrics suggested a compelling entry point for investors, supported by strong returns on capital employed (44.14%) and equity (23.46%).
On 18 May, the stock closed at ₹2,340.45, up 0.67% on the day, outperforming the Sensex which declined 0.35%. This positive price action reflected renewed investor interest following the valuation update.
19 May: Upgrade to Strong Buy on Robust Financials and Technical Momentum
The following day, Glenmark was upgraded from a Buy to a Strong Buy rating by MarketsMOJO, with its Mojo Score rising to 81.0. This upgrade was driven by improved valuation metrics, including a P/E of 27.85 and a very low PEG ratio of 0.03, alongside robust financial performance. The company reported net sales of ₹9,947.49 crores for the latest six months, a 45.83% increase, and profit after tax surged by 890.4% to ₹2,026.77 crores.
On 19 May, the stock surged 2.77% to close at ₹2,405.25, nearing its 52-week high of ₹2,471.05. This price gain outpaced the Sensex’s 0.25% rise, reflecting strong technical momentum and investor confidence following the rating upgrade.
Quarter after quarter, this Small Cap from the Lifestyle sector delivers without fail! Just added to our Reliable Performers with proven staying power. Stability meets growth here beautifully.
- - Consistent quarterly delivery
- - Proven staying power
- - Stability with growth
21 May: Sharp Open Interest Surge Signals Bullish Market Positioning
On 21 May, Glenmark Pharmaceuticals saw a significant 17.37% increase in open interest in its derivatives segment, rising to 47,848 contracts. This surge was accompanied by strong volume of 25,731 contracts and a futures notional value of ₹1,26,828.26 lakhs. The stock price closed at ₹2,389.55, up 0.50%, outperforming the Pharmaceuticals & Biotechnology sector and the Sensex.
The rise in open interest alongside increasing prices and delivery volumes suggested fresh bullish positions being established by traders. The stock traded above all key moving averages, signalling sustained technical strength and positive market sentiment.
21 May: Technical Momentum Shift Reinforces Strong Buy Rating
Despite a minor intraday decline of 1.15% on 20 May, Glenmark’s technical indicators remained predominantly bullish. The Moving Average Convergence Divergence (MACD) on weekly and monthly charts continued to signal strength, while the Relative Strength Index (RSI) showed neutral readings, indicating room for further price appreciation without overbought conditions.
The stock’s Mojo Grade was upgraded to Strong Buy on 19 May, reflecting this positive technical momentum combined with robust fundamentals. Glenmark’s one-year return of 66.03% and three-year return of 280.91% significantly outperformed the Sensex, underscoring its strong market position.
22 May: Intraday Low Amid Price Pressure and Volatile Trading
On 22 May, Glenmark Pharmaceuticals experienced notable intraday weakness, falling 5.46% to close at ₹2,259.20. The stock touched an intraday low of ₹2,272, underperforming the broader market which gained 0.21% that day. This decline reflected short-term selling pressure, with the stock trading below its 5-day and 20-day moving averages despite remaining above longer-term averages.
Technical indicators presented a mixed picture, with bullish MACD and Bollinger Bands offset by mildly bearish KST and Dow Theory signals. The divergence between price weakness and broader market strength suggested sector-specific caution and profit booking by traders near recent highs.
Want to dive deeper on Glenmark Pharmaceuticals Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
22 May: Open Interest Surges 27.6% Amid Volatile Trading
Despite the price decline, Glenmark’s derivatives open interest surged 27.61% to 52,195 contracts on 22 May, with total volume reaching 94,022 contracts. The futures segment’s notional value was approximately ₹2,04,118 lakhs, while options accounted for ₹61,648.3 crores, indicating intense trading activity and repositioning by market participants.
The weighted average price of traded contracts skewed near the day’s low, signalling bearish sentiment among traders. Delivery volumes declined sharply by 54.67%, suggesting reduced long-term holding despite active derivatives trading. This combination pointed to a complex market environment with increased hedging and short-term speculative activity amid uncertainty.
Daily Price Comparison: Glenmark Pharmaceuticals vs Sensex (18-22 May 2026)
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-18 | Rs.2,340.45 | +0.67% | 35,114.86 | -0.35% |
| 2026-05-19 | Rs.2,405.25 | +2.77% | 35,201.48 | +0.25% |
| 2026-05-20 | Rs.2,377.65 | -1.15% | 35,299.20 | +0.28% |
| 2026-05-21 | Rs.2,389.55 | +0.50% | 35,340.31 | +0.12% |
| 2026-05-22 | Rs.2,259.20 | -5.46% | 35,413.94 | +0.21% |
Key Takeaways
Positive Signals: Glenmark Pharmaceuticals demonstrated strong fundamental improvements with a very attractive valuation profile, robust financial growth, and a significant upgrade to a Strong Buy rating. The stock showed technical resilience, trading above key long-term moving averages and supported by bullish MACD signals. The surge in open interest on 21 May indicated fresh bullish positioning by derivatives traders.
Cautionary Signals: Despite these positives, the stock faced notable short-term selling pressure on 22 May, closing the week down 2.83% and underperforming the Sensex by 3.33%. The sharp increase in open interest amid price weakness and declining delivery volumes suggested heightened volatility and possible hedging or short-selling activity. Mixed technical indicators such as mildly bearish KST and weekly OBV readings warrant close monitoring for potential consolidation or correction phases.
Conclusion
Glenmark Pharmaceuticals’ week was characterised by a strong fundamental and technical backdrop overshadowed by short-term volatility and price pressure. The company’s upgraded Strong Buy rating, attractive valuation metrics, and robust financial performance underpin a positive medium- to long-term outlook. However, the sharp intraday declines and elevated derivatives activity on 22 May highlight the need for caution amid near-term market uncertainty. Investors should watch for confirmation of trend direction in coming sessions, balancing Glenmark’s solid fundamentals against the current unsettled trading environment.
53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today
